Novo Nordisk A/S (NYSE:NVO) Shares Sold by MN Wealth Advisors LLC

MN Wealth Advisors LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 6.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,782 shares of the company’s stock after selling 206 shares during the quarter. MN Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $28,000. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $48,000. Finally, Dunhill Financial LLC grew its holdings in shares of Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.1 %

Shares of NVO opened at $77.94 on Friday. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $349.75 billion, a price-to-earnings ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45. The stock’s 50-day moving average price is $88.65 and its 200 day moving average price is $109.83.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts predict that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 21.88%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday. They set an “equal weight” rating on the stock. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.